VanEck Gold Miners ETF vs Relay Therapeutics Inc. Common Stock — how do they compare? VanEck Gold Miners ETF trades at $88.64 (market cap $25.65B), while Relay Therapeutics Inc. Common Stock trades at $17.59 (market cap $3.82B). The key difference: VanEck Gold Miners ETF is far larger — about 6.7× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| GDX | RLAY | |
|---|---|---|
Market Cap | $25.65B | $3.82B |
Volume | 16,534,046 | 4,332,079 |
52-Week High | $115.84 | $20.75 |
52-Week Low | $68.28 | $6.03 |
Typical Hold Time | 76 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.93B |
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $85.46, down 3.13% amid a bearish technical signal with 13 sell signals from moving averages. Recent news highlights pressure on gold miners from rising interest rates and silver's sharp decline, though some analysts see value in the sell-off. Key support lies at $84, with resistance at $86-87. The ETF offers exposure to gold mining equities but lacks disclosed fundamental ratios in this snapshot.
The outlook for GDX hinges on gold price direction and interest rate trends, with risks including metal volatility and macroeconomic headwinds. Opportunities exist if gold rebounds, but investor caution is warranted given technical weakness and mixed sentiment from institutional flows.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →